PC-Trial: Patent Foramen Ovale and Cryptogenic Embolism

PHASE4UnknownINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

February 29, 2000

Primary Completion Date

February 28, 2011

Study Completion Date

May 31, 2011

Conditions
Embolism, ParadoxicalHeart Septal Defects, Atrial
Interventions
DEVICE

Percutaneous closure of patent foramen ovale

Percutaneous implantation of an AMPLATZER® PFO Occluder

DRUG

Medical antitrhombotic treatment

Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d

Trial Locations (6)

1090

Universitätsklinik für Innere Medizin II, Vienna

8000

A.Z. Sint-Jan AV, Bruges

Unknown

Monash Medical Centre, Melbourne

Sir Charles Gairdner Hospital, Nedlands

Alfred Hospital, Prahan

University Hospital / Inselspital, Bern

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Abbott Medical Devices

INDUSTRY

lead

Foundation for Cardiovascular Research, Zurich

OTHER